These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 25633038)

  • 1. Ki67 index is an independent prognostic factor in epithelioid but not in non-epithelioid malignant pleural mesothelioma: a multicenter study.
    Ghanim B; Klikovits T; Hoda MA; Lang G; Szirtes I; Setinek U; Rozsas A; Renyi-Vamos F; Laszlo V; Grusch M; Filipits M; Scheed A; Jakopovic M; Samarzija M; Brcic L; Stancic-Rokotov D; Kern I; Rozman A; Dekan G; Klepetko W; Berger W; Glasz T; Dome B; Hegedus B
    Br J Cancer; 2015 Mar; 112(5):783-92. PubMed ID: 25633038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications.
    Forest F; Patoir A; Dal Col P; Sulaiman A; Camy F; Laville D; Bayle-Bleuez S; Fournel P; Habougit C
    Pathology; 2018 Oct; 50(6):635-641. PubMed ID: 30145072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.
    Brosseau S; Danel C; Scherpereel A; Mazières J; Lantuejoul S; Margery J; Greillier L; Audigier-Valette C; Gounant V; Antoine M; Moro-Sibilot D; Rouquette I; Molinier O; Corre R; Monnet I; Langlais A; Morin F; Bergot E; Zalcman G; Levallet G
    Clin Lung Cancer; 2019 Sep; 20(5):e564-e575. PubMed ID: 31279641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amount of Epithelioid Differentiation Is a Predictor of Survival in Malignant Pleural Mesothelioma.
    Vigneswaran WT; Kircheva DY; Ananthanarayanan V; Watson S; Arif Q; Celauro AD; Kindler HL; Husain AN
    Ann Thorac Surg; 2017 Mar; 103(3):962-966. PubMed ID: 27765170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
    Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
    Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of the Stem Cell Factor Nestin in Malignant Pleural Mesothelioma Is Associated with Poor Prognosis.
    Thies S; Friess M; Frischknecht L; Korol D; Felley-Bosco E; Stahel R; Vrugt B; Weder W; Opitz I; Soltermann A
    PLoS One; 2015; 10(9):e0139312. PubMed ID: 26421614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumoral CD10 expression correlates with aggressive histology and prognosis in patients with malignant pleural mesothelioma.
    Kadota K; Villena-Vargas J; Nitadori J; Sima CS; Jones DR; Travis WD; Adusumilli PS
    Ann Surg Oncol; 2015 Sep; 22(9):3136-43. PubMed ID: 25608772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of SKIP expression in malignant pleural mesotheliomas with Ki-67 proliferation index and prognostic parameters.
    Türkcü G; AlabalIk U; Keles AN; Ibiloglu I; Küçüköner M; Sen HS; Büyükbayram H
    Pol J Pathol; 2016 Jun; 67(2):108-13. PubMed ID: 27543864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ratio of intratumoral macrophage phenotypes is a prognostic factor in epithelioid malignant pleural mesothelioma.
    Cornelissen R; Lievense LA; Maat AP; Hendriks RW; Hoogsteden HC; Bogers AJ; Hegmans JP; Aerts JG
    PLoS One; 2014; 9(9):e106742. PubMed ID: 25192022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of Ki67 expression in malignant peritoneal mesothelioma.
    Pillai K; Pourgholami MH; Chua TC; Morris DL
    Am J Clin Oncol; 2015 Aug; 38(4):388-94. PubMed ID: 26214083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contemporary Analysis of Prognostic Factors in Patients with Unresectable Malignant Pleural Mesothelioma.
    Billé A; Krug LM; Woo KM; Rusch VW; Zauderer MG
    J Thorac Oncol; 2016 Feb; 11(2):249-55. PubMed ID: 26845118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors in elderly patients with malignant pleural mesothelioma: results of a multicenter survey.
    Ceresoli GL; Grosso F; Zucali PA; Mencoboni M; Pasello G; Ripa C; Degiovanni D; Simonelli M; Bruzzone A; Dipietrantonj C; Piccolini E; Beretta GD; Favaretto AG; Giordano L; Santoro A; Botta M
    Br J Cancer; 2014 Jul; 111(2):220-6. PubMed ID: 24918816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of metabolic response by positron emission tomography after neoadjuvant chemotherapy for resectable malignant pleural mesothelioma.
    Tsutani Y; Takuwa T; Miyata Y; Fukuoka K; Hasegawa S; Nakano T; Okada M
    Ann Oncol; 2013 Apr; 24(4):1005-10. PubMed ID: 23136224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma.
    Kadota K; Suzuki K; Colovos C; Sima CS; Rusch VW; Travis WD; Adusumilli PS
    Mod Pathol; 2012 Feb; 25(2):260-71. PubMed ID: 21983936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).
    Cedrés S; Ponce-Aix S; Zugazagoitia J; Sansano I; Enguita A; Navarro-Mendivil A; Martinez-Marti A; Martinez P; Felip E
    PLoS One; 2015; 10(3):e0121071. PubMed ID: 25774992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mdm2 protein expression is strongly associated with survival in malignant pleural mesothelioma.
    Mairinger FD; Walter RF; Ting S; Vollbrecht C; Kollmeier J; Griff S; Hager T; Mairinger T; Christoph DC; Theegarten D; Schmid KW; Wohlschlaeger J
    Future Oncol; 2014 May; 10(6):995-1005. PubMed ID: 24941985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales.
    Linton A; Pavlakis N; O'Connell R; Soeberg M; Kao S; Clarke S; Vardy J; van Zandwijk N
    Br J Cancer; 2014 Oct; 111(9):1860-9. PubMed ID: 25188323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of Nuclear Grading System in Epithelioid Malignant Pleural Mesothelioma in Biopsy-heavy Setting: An External Validation Study of 563 Cases.
    Zhang YZ; Brambilla C; Molyneaux PL; Rice A; Robertus JL; Jordan S; Lim E; Lang-Lazdunski L; Begum S; Dusmet M; Anikin V; Beddow E; Finch J; Asadi N; Popat S; Cookson WOC; Moffatt MF; Nicholson AG
    Am J Surg Pathol; 2020 Mar; 44(3):347-356. PubMed ID: 32045387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival by Histologic Subtype of Malignant Pleural Mesothelioma and the Impact of Surgical Resection on Overall Survival.
    Verma V; Ahern CA; Berlind CG; Lindsay WD; Shabason J; Sharma S; Culligan MJ; Grover S; Friedberg JS; Simone CB
    Clin Lung Cancer; 2018 Nov; 19(6):e901-e912. PubMed ID: 30224273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy Versus Supportive Care for Unresected Malignant Pleural Mesothelioma.
    Verma V; Wegner RE; Brooks ED; Miccio JA; Kann BH; Finley GG; Raj MS; Grover S; Mohindra P; Simone CB
    Clin Lung Cancer; 2019 Jul; 20(4):263-269. PubMed ID: 30992187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.